Ireland - English - HPRA (Health Products Regulatory Authority)

ceva animal health limited - selegiline hydrochloride - film-coated tablet - 3.35 mg/tablet - antidepressants - dogs - neurological preparations

New Zealand - English - Medsafe (Medicines Safety Authority)

psm healthcare ltd trading as api consumer brands - atorvastatin calcium trihydrate 10.825mg equivalent to atorvastatin 10 mg - film coated tablet - 10 mg - active: atorvastatin calcium trihydrate 10.825mg equivalent to atorvastatin 10 mg excipient: butylated hydroxyanisole colloidal silicon dioxide croscarmellose sodium sepifilm lp 010 magnesium stearate mannitol microcrystalline cellulose purified water sodium carbonate sodium laurilsulfate - indicated as an adjunct to diet to reduce elevated total-c, ldl-c and tg levels in patients with primary hypercholesterolaemia or mixed dyslipidaemia where the primary abnormality is either elevated cholesterol or triglycerides when response to diet and other non-pharmacological measures is inadequate. atorvastatin tablet is also indicated to reduce total-c and ldl-c in patients with heterozygous and homozygous familial hypercholesterolaemia.

New Zealand - English - Medsafe (Medicines Safety Authority)

psm healthcare ltd trading as api consumer brands - atorvastatin calcium trihydrate 21.65mg equivalent to atorvastatin 20 mg - film coated tablet - 20 mg - active: atorvastatin calcium trihydrate 21.65mg equivalent to atorvastatin 20 mg excipient: butylated hydroxyanisole colloidal silicon dioxide croscarmellose sodium sepifilm lp 010 magnesium stearate mannitol microcrystalline cellulose purified water sodium carbonate sodium laurilsulfate - indicated as an adjunct to diet to reduce elevated total-c, ldl-c and tg levels in patients with primary hypercholesterolaemia or mixed dyslipidaemia where the primary abnormality is either elevated cholesterol or triglycerides when response to diet and other non-pharmacological measures is inadequate. atorvastatin tablet is also indicated to reduce total-c and ldl-c in patients with heterozygous and homozygous familial hypercholesterolaemia.

New Zealand - English - Medsafe (Medicines Safety Authority)

psm healthcare ltd trading as api consumer brands - atorvastatin calcium trihydrate 43.3mg equivalent to atorvastatin 40 mg - film coated tablet - 40 mg - active: atorvastatin calcium trihydrate 43.3mg equivalent to atorvastatin 40 mg excipient: butylated hydroxyanisole colloidal silicon dioxide croscarmellose sodium sepifilm lp 010 magnesium stearate mannitol microcrystalline cellulose purified water sodium carbonate sodium laurilsulfate - indicated as an adjunct to diet to reduce elevated total-c, ldl-c and tg levels in patients with primary hypercholesterolaemia or mixed dyslipidaemia where the primary abnormality is either elevated cholesterol or triglycerides when response to diet and other non-pharmacological measures is inadequate. atorvastatin tablet is also indicated to reduce total-c and ldl-c in patients with heterozygous and homozygous familial hypercholesterolaemia.

New Zealand - English - Medsafe (Medicines Safety Authority)

psm healthcare ltd trading as api consumer brands - atorvastatin calcium trihydrate 86.6mg equivalent to atorvastatin 80 mg - film coated tablet - 80 mg - active: atorvastatin calcium trihydrate 86.6mg equivalent to atorvastatin 80 mg excipient: butylated hydroxyanisole colloidal silicon dioxide croscarmellose sodium sepifilm lp 010 magnesium stearate mannitol microcrystalline cellulose purified water sodium carbonate sodium laurilsulfate - indicated as an adjunct to diet to reduce elevated total-c, ldl-c and tg levels in patients with primary hypercholesterolaemia or mixed dyslipidaemia where the primary abnormality is either elevated cholesterol or triglycerides when response to diet and other non-pharmacological measures is inadequate. atorvastatin tablet is also indicated to reduce total-c and ldl-c in patients with heterozygous and homozygous familial hypercholesterolaemia.

New Zealand - English - Medsafe (Medicines Safety Authority)

jntl consumer health (new zealand) limited - nicotine polacrilex 10mg equivalent to 2 mg nictoine (plus 5% overage);   - lozenge - 2 mg - active: nicotine polacrilex 10mg equivalent to 2 mg nictoine (plus 5% overage)   excipient: acesulfame potassium   hypromellose magnesium stearate mannitol polysorbate 80 purified water sepifilm gloss sodium carbonate sucralose   titanium dioxide tutti frutti flavour aj-048-581-4 tutti frutti flavour rd-283-476-8 xanthan gum - for the treatment of tobacco dependence by relieving nicotine craving and withdrawal symptoms.

New Zealand - English - Medsafe (Medicines Safety Authority)

jntl consumer health (new zealand) limited - nicotine polacrilex 20mg equivalent to 4 mg nicotine (plus 5% overage);   - lozenge - 4 mg - active: nicotine polacrilex 20mg equivalent to 4 mg nicotine (plus 5% overage)   excipient: acesulfame potassium   hypromellose magnesium stearate mannitol polysorbate 80 purified water sepifilm gloss sodium carbonate sucralose   titanium dioxide tutti frutti flavour aj-048-581-4 tutti frutti flavour rd-283-476-8 xanthan gum - for the treatment of tobacco dependence by relieving nicotine craving and withdrawal symptoms.

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - oxycodone hydrochloride 10mg;   - modified release tablet - 10 mg - active: oxycodone hydrochloride 10mg   excipient: colloidal silicon dioxide copovidone hydrogenated castor oil glycerol(mono,tri)docosanoat [behenoyl polyoxyglyerides] lactose monohydrate magnesium stearate maize starch medium-chain triglycerides sepifilm white lp761 - the management of moderate to severe chronic pain unresponsive to non-narcotic analgesia.

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - oxycodone hydrochloride 20mg;   - modified release tablet - 20 mg - active: oxycodone hydrochloride 20mg   excipient: colloidal silicon dioxide copovidone hydrogenated castor oil glycerol(mono,tri)docosanoat [behenoyl polyoxyglycerides] iron oxide red lactose monohydrate magnesium stearate maize starch medium-chain triglycerides sepifilm white lp761 - the management of moderate to severe chronic pain unresponsive to non-narcotic analgesia.

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - oxycodone hydrochloride 40mg;   - modified release tablet - 40 mg - active: oxycodone hydrochloride 40mg   excipient: colloidal silicon dioxide copovidone hydrogenated castor oil glycerol(mono,tri)docosanoat [behenoyl polyoxyglycerides] iron oxide yellow lactose monohydrate magnesium stearate maize starch medium-chain triglycerides sepifilm white lp761 - the management of moderate to severe chronic pain unresponsive to non-narcotic analgesia.